HOME > Articles >

Korean J Gastroenterol  <  Volume 78(3); 2021 <  Articles

Korean J Gastroenterol 2021; 78(3): 202-203  https://doi.org/10.4166/kjg.2021.78.3.202
KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement
Yong Eun Park1*, Yoo Jin Lee2*, Ji Young Chang3, Hyun Joo Song4, Duk Hwan Kim5, Young Joo Yang6, Byung Chang Kim7, Jae Gon Lee8, Hee Chan Yang9, Miyoung Choi10, Seong-Eun Kim11*, Seung-Jae Myung12*, The Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases
Division of Gastroenterology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine1, Busan; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine2, Daegu; Department of Health Promotion Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine3, Seoul; Division of Gastroenterology, Department of Internal Medicine, Jeju National University Hospital, Jeju National University College of Medicine4, Jeju; Digestive Disease Center, CHA Bundang Hospital, CHA University5, Seongnam; Division of Gastroenterology, Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine6, Chuncheon; Center for Colorectal Cancer, National Cancer Center7, Goyang; Division of Gastroenterology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine8, Hwaseong; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jeonbuk National University Hospital, Jeonbuk National University Medical School9, Jeonju; Division of Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency10, Seoul; Division of Gastroenterology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine11, Seoul; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine12, Seoul, Korea
Published online: September 25, 2021.
© The Korean Journal of Gastroenterology. All rights reserved.

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Korean J Gastroenterol 2021;78:105-116 https://doi.org/10.4166/kjg.2021.112

대한소화기학회지에 게재된 위 논문에서 초록을 정정합니다.

This correction is being published to correct the abstract in above article.

Before correction

The coronavirus disease 2019 (COVID-19) pandemic has reduced the ability to prevent or control chronic disease due to the concerns about safety in accessing health care. Inflammatory bowel disease (IBD) is a chronic condition requiring long- term sustained treatment, which is difficult in the current panedemic situation. The Korean Association for the Study of Intestinal Diseases (KASID) has developed an expert consensus statement on the clinical practice management of adult inflammatory bowel disease during the COVID-19 pandemic. This expert consensus statement is based on guidelines and clinical reports from several countries around the world. It provides recommendations to deal with the risk of COVID-19 and medication use in IBD patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and emphasizes the importance of right treatment approach to avoid worsening of the disease condition in IBD patients.

After correction

Many unexpected problems have resulted from the unprecedented COVID-19 pandemic. The optimal management of patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic has also been a challenge. Therefore, the Korean Association for the Study of Intestinal Diseases (KASID) developed a consensus statement of experts regarding the management of IBD during the COVID-19 pandemic. This consensus statement made recommendations regarding the risk and treatment of COVID-19 in IBD patients. This statement emphasizes that IBD is not a risk factor for COVID-19, and care should be taken not to exacerbate IBD in patients in remission state by maintaining their medications, except for corticosteroids.



This Article


Stats or Metrics
  • View: 86
  • Download: 81

Services
Social Network Service

e-submission

Archives

Official Journal of

Indexed/Covered by

  • thomson reuters
  • koreamed
  • crossref
  • google
  • synepse
  • kofst
  • DOAJ
  • ORCID